Keros Therapeutics Valuation
Is KROS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KROS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate KROS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate KROS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KROS?
Key metric: As KROS barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is KROS's PB Ratio? | |
|---|---|
| PB Ratio | 4.1x |
| Book | US$532.84m |
| Market Cap | US$2.17b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2550.9x |
| Enterprise Value/EBITDA | -8.2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does KROS's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 48.7x | ||
SRRK Scholar Rock Holding | 32.9x | 48.8% | US$2.6b |
XENE Xenon Pharmaceuticals | 3.8x | 12.7% | US$3.0b |
SNDX Syndax Pharmaceuticals | 3.7x | 25.7% | US$1.3b |
INBX Inhibrx | 154.5x | 9.1% | US$1.8b |
KROS Keros Therapeutics | 4.1x | -5.0% | US$2.2b |
Price-To-Book vs Peers: KROS is good value based on its Price-To-Book Ratio (4.1x) compared to the peer average (48.7x).
Price to Book Ratio vs Industry
How does KROS's PB Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: KROS is expensive based on its Price-To-Book Ratio (4.1x) compared to the US Biotechs industry average (1.8x).
Price to Book Ratio vs Fair Ratio
What is KROS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 4.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate KROS's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$54.14 | US$90.69 +67.5% | 12.0% | US$107.00 | US$76.00 | n/a | 13 |
| Nov ’25 | US$59.94 | US$89.33 +49.0% | 11.6% | US$105.00 | US$76.00 | n/a | 12 |
| Oct ’25 | US$59.79 | US$90.90 +52.0% | 11.5% | US$105.00 | US$76.00 | n/a | 10 |
| Sep ’25 | US$45.35 | US$90.89 +100.4% | 11.2% | US$105.00 | US$77.00 | n/a | 9 |
| Aug ’25 | US$50.36 | US$90.56 +79.8% | 11.8% | US$105.00 | US$74.00 | n/a | 9 |
| Jul ’25 | US$43.77 | US$90.10 +105.8% | 11.4% | US$105.00 | US$74.00 | n/a | 10 |
| Jun ’25 | US$46.87 | US$88.78 +89.4% | 11.2% | US$105.00 | US$74.00 | n/a | 9 |
| May ’25 | US$57.72 | US$88.11 +52.7% | 11.4% | US$105.00 | US$77.00 | n/a | 9 |
| Apr ’25 | US$66.89 | US$88.11 +31.7% | 11.4% | US$105.00 | US$77.00 | n/a | 9 |
| Mar ’25 | US$68.85 | US$85.30 +23.9% | 14.9% | US$105.00 | US$60.00 | n/a | 10 |
| Feb ’25 | US$57.22 | US$81.89 +43.1% | 20.0% | US$105.00 | US$60.00 | n/a | 9 |
| Jan ’25 | US$39.76 | US$81.89 +106.0% | 20.0% | US$105.00 | US$60.00 | n/a | 9 |
| Dec ’24 | US$30.64 | US$87.75 +186.4% | 18.9% | US$105.00 | US$60.00 | n/a | 8 |
| Nov ’24 | US$28.59 | US$90.25 +215.7% | 16.3% | US$110.00 | US$66.00 | US$59.94 | 8 |
| Oct ’24 | US$31.88 | US$90.25 +183.1% | 16.3% | US$110.00 | US$66.00 | US$59.79 | 8 |
| Sep ’24 | US$36.24 | US$90.25 +149.0% | 16.3% | US$110.00 | US$66.00 | US$45.35 | 8 |
| Aug ’24 | US$41.11 | US$90.13 +119.2% | 16.6% | US$110.00 | US$65.00 | US$50.36 | 8 |
| Jul ’24 | US$40.18 | US$95.00 +136.4% | 13.6% | US$110.00 | US$75.00 | US$43.77 | 6 |
| Jun ’24 | US$47.80 | US$95.00 +98.7% | 13.6% | US$110.00 | US$75.00 | US$46.87 | 6 |
| May ’24 | US$46.07 | US$96.67 +109.8% | 15.7% | US$120.00 | US$75.00 | US$57.72 | 6 |
| Apr ’24 | US$42.70 | US$96.67 +126.4% | 15.7% | US$120.00 | US$75.00 | US$66.89 | 6 |
| Mar ’24 | US$54.76 | US$96.67 +76.5% | 15.7% | US$120.00 | US$75.00 | US$68.85 | 6 |
| Feb ’24 | US$58.27 | US$96.67 +65.9% | 15.7% | US$120.00 | US$75.00 | US$57.22 | 6 |
| Jan ’24 | US$48.02 | US$96.67 +101.3% | 15.7% | US$120.00 | US$75.00 | US$39.76 | 6 |
| Dec ’23 | US$50.09 | US$95.00 +89.7% | 15.5% | US$120.00 | US$75.00 | US$30.64 | 6 |
| Nov ’23 | US$50.69 | US$95.00 +87.4% | 15.5% | US$120.00 | US$75.00 | US$28.59 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Collegium Pharmaceutical
US$959.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.00
7D
-0.6%
1Y
15.5%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.10
7D
-7.9%
1Y
6.6%
IQVIA Holdings
US$34.7b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$194.38
7D
-8.1%
1Y
-7.2%